Role of medical comorbidity in the association between psychiatric disorders and mortality among patients with COVID-19. 2022

Gonzalo Martínez-Alés, and Eduardo Fernández-Jiménez, and Roberto Mediavilla, and Manuel Quintana-Díaz, and Iker Louzao, and Susana Cebolla, and Ainoa Muñoz-Sanjosé, and Carmen Bayón, and Ezra S Susser, and María Fe Bravo-Ortiz, and
Harvard University T.H. Chan School of Public Health, Boston, MA, USA. gmartinezales@hsph.harvard.edu.

We examined whether excess chronic medical comorbidity mediated excess COVID-19 inpatient mortality among people with mental disorders in the early phase of the pandemic, a question with important implications for public health and clinical decision-making. Using records of 2599 COVID-19 hospitalized patients, we conducted a formal causal mediation analysis to estimate the extent to which chronic comorbidity mediates the association between mental disorders and COVID-19 mortality. The Odds Ratio (95% CI) for Natural Indirect Effect and Controlled Direct Effect were 1.07(1.02, 1.14) and 1.40 (1.00, 1.95), respectively, suggesting that a large proportion of excess COVID-19 mortality among people with mental disorders may be explained by factors other than comorbidity.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D001523 Mental Disorders Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function. Mental Illness,Psychiatric Diseases,Psychiatric Disorders,Psychiatric Illness,Behavior Disorders,Diagnosis, Psychiatric,Mental Disorders, Severe,Psychiatric Diagnosis,Illness, Mental,Mental Disorder,Mental Disorder, Severe,Mental Illnesses,Psychiatric Disease,Psychiatric Disorder,Psychiatric Illnesses,Severe Mental Disorder,Severe Mental Disorders
D015897 Comorbidity The presence of co-existing or additional diseases with reference to an initial diagnosis or with reference to the index condition that is the subject of study. Comorbidity may affect the ability of affected individuals to function and also their survival; it may be used as a prognostic indicator for length of hospital stay, cost factors, and outcome or survival.
D058873 Pandemics Epidemics of infectious disease that have spread to many countries, often more than one continent, and usually affecting a large number of people. Pandemic

Related Publications

Gonzalo Martínez-Alés, and Eduardo Fernández-Jiménez, and Roberto Mediavilla, and Manuel Quintana-Díaz, and Iker Louzao, and Susana Cebolla, and Ainoa Muñoz-Sanjosé, and Carmen Bayón, and Ezra S Susser, and María Fe Bravo-Ortiz, and
June 2023, Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999),
Gonzalo Martínez-Alés, and Eduardo Fernández-Jiménez, and Roberto Mediavilla, and Manuel Quintana-Díaz, and Iker Louzao, and Susana Cebolla, and Ainoa Muñoz-Sanjosé, and Carmen Bayón, and Ezra S Susser, and María Fe Bravo-Ortiz, and
April 2021, JAMA psychiatry,
Gonzalo Martínez-Alés, and Eduardo Fernández-Jiménez, and Roberto Mediavilla, and Manuel Quintana-Díaz, and Iker Louzao, and Susana Cebolla, and Ainoa Muñoz-Sanjosé, and Carmen Bayón, and Ezra S Susser, and María Fe Bravo-Ortiz, and
December 1996, Psychiatric services (Washington, D.C.),
Gonzalo Martínez-Alés, and Eduardo Fernández-Jiménez, and Roberto Mediavilla, and Manuel Quintana-Díaz, and Iker Louzao, and Susana Cebolla, and Ainoa Muñoz-Sanjosé, and Carmen Bayón, and Ezra S Susser, and María Fe Bravo-Ortiz, and
November 2021, JAMA network open,
Gonzalo Martínez-Alés, and Eduardo Fernández-Jiménez, and Roberto Mediavilla, and Manuel Quintana-Díaz, and Iker Louzao, and Susana Cebolla, and Ainoa Muñoz-Sanjosé, and Carmen Bayón, and Ezra S Susser, and María Fe Bravo-Ortiz, and
January 2023, The European journal of psychiatry,
Gonzalo Martínez-Alés, and Eduardo Fernández-Jiménez, and Roberto Mediavilla, and Manuel Quintana-Díaz, and Iker Louzao, and Susana Cebolla, and Ainoa Muñoz-Sanjosé, and Carmen Bayón, and Ezra S Susser, and María Fe Bravo-Ortiz, and
November 2021, The primary care companion for CNS disorders,
Gonzalo Martínez-Alés, and Eduardo Fernández-Jiménez, and Roberto Mediavilla, and Manuel Quintana-Díaz, and Iker Louzao, and Susana Cebolla, and Ainoa Muñoz-Sanjosé, and Carmen Bayón, and Ezra S Susser, and María Fe Bravo-Ortiz, and
February 2021, The Journal of infection,
Gonzalo Martínez-Alés, and Eduardo Fernández-Jiménez, and Roberto Mediavilla, and Manuel Quintana-Díaz, and Iker Louzao, and Susana Cebolla, and Ainoa Muñoz-Sanjosé, and Carmen Bayón, and Ezra S Susser, and María Fe Bravo-Ortiz, and
January 2022, Journal of thrombosis and thrombolysis,
Gonzalo Martínez-Alés, and Eduardo Fernández-Jiménez, and Roberto Mediavilla, and Manuel Quintana-Díaz, and Iker Louzao, and Susana Cebolla, and Ainoa Muñoz-Sanjosé, and Carmen Bayón, and Ezra S Susser, and María Fe Bravo-Ortiz, and
June 2022, The American journal of emergency medicine,
Gonzalo Martínez-Alés, and Eduardo Fernández-Jiménez, and Roberto Mediavilla, and Manuel Quintana-Díaz, and Iker Louzao, and Susana Cebolla, and Ainoa Muñoz-Sanjosé, and Carmen Bayón, and Ezra S Susser, and María Fe Bravo-Ortiz, and
June 2020, Mayo Clinic proceedings,
Copied contents to your clipboard!